Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer

Maurie Markman, MD


November 23, 2021

Figure 1. Lung cancer in a 50-year-old smoker.

Unlike in breast and gastric cancer, HER2 overexpression is not validated to be a biomarker predictive of clinical response to HER2-targeted agents in NSCLC. Similar to epidermal growth factor receptor (EGFR) mutations, the incidence of HER2 mutations is significantly increased in nonsmokers and women, as well as persons of Asian descent and those with adenocarcinoma NSCLCs.

HER2 overexpression is detected in less than 20% of patients with NSCLC. It is associated with poor prognosis in both resected and advanced NSCLC.

Learn more about NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.